Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
NCT06564753 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
- Lead sponsor
- Biomed Industries, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 19, 2024
- Completion date
- April 18, 2025
- Enrollment
- 126 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.